

Republic of Iraq
Ministry of Higher Education
and Scientific Research
University of Baghdad
College of Pharmacy



*Preparation of chitosan from natural Waste Product
and evaluation of its use as a retardant in Sustained
release tablets*

A Thesis

*Submitted to the Department of Pharmaceutics and the
Committee of Graduate Studies of the College of
Pharmacy-University of Baghdad in Partial Fulfilment
of the Requirements for the Degree of Master of Science
in Pharmacy (Pharmaceutics)*

By

Mohammed Sabar Al-Lami

B.Sc. Pharmacy

2001

Supervised by

Prof.

Alaa A. Abdul-Rasool

ABSTRACT

This study was carried out in order to prepare a polymer from natural waste product that has a retardation effect to be used in sustained release tablets. Chitosan polymer was prepared from waste prawn shells by alkaline N-deacetylation of chitin which was separated from those shells by demineralization with acid and deproteination with alkaline at 95° C.

The average molecular weight range of the prepared chitosan using viscosity method was (12225-12745) gm/mole. Chitosan retardation effect was studied by formulation of chitosan matrix tablets that were prepared by direct compression technique containing serial percentages of chitosan utilizing the model drugs orphenadrine citrate as sparingly water soluble and theophylline as slightly water soluble.

Hardness and dissolution tests of the prepared tablets were determined. Results showed that chitosan had a retardation effect. The mechanisms of release were erosion at pH 1.2 and diffusion at pH 6.8 dissolution media.

On the other hand, the release of drugs was found to be affected by type of drug, percentage of chitosan and compression force. It appears that the release of drug from chitosan matrix tablets increased as the solubility of drug in dissolution media increased. While the release rate of drug decreased as the percentage of chitosan increased. Further more, the release of drug increased as the compression force decreased by (1000psi) and the hardness had a linear regression with logarithm of compression force.

The data also showed that chitosan matrix tablets containing 40% chitosan had a sustained effect more than that filled in hard gelatin capsules. The

compressed chitosan appeared to be responsible for sustaining the release of drugs.

The release of orphenadrine citrate from norflex[®] tablets was compared with the prepared chitosan matrix tablets containing 30% of chitosan and compressed at $37 \cdot 10^3$ psi. No significant difference between two products was observed.

Chitosan HCl and acetate salts were also prepared. The effect of chitosan HCl and acetate on the release of orphenadrine citrate and theophylline in their matrix tablets was studied. The results showed that they increased the disintegration time, i.e they had a disintegrant property.

CONTENTS

Acknowledgments	V
Abstract	VI
Contents	VIII
List of Tables	XI
List of Figures	XII
Scheme	XV

CHAPTER ONE

(INTRODUCTION)

1.1	Sustained Release Drug Delivery Systems.....	1
1.2	Potential Advantages of Sustained Drug Therapy.....	1
1.3	Drug Properties Relevant for Sustained Release Formulations.....	2
1.3.1	Physicochemical Properties.....	2
1.3.2	Biological Properties.....	3
1.4	Methods Used to Achieve Sustained Release of Oral Administered Drugs	5
1.5	Practical Formulation of Matrix Tablet Sustained Release Product.....	8
1.6	Materials Used as Retardant in Matrix Tablet Formulations.....	9
1.6.1	Insoluble, Inert Polymers.....	9
1.6.2	Insoluble Erodable Materials.....	10
1.6.3	Hydrophilic Polymers.....	10
1.6.4	Miscellaneous Materials.....	11
1.7	Evaluation of Sustained Release Tablets.....	16
1.8	The Model Drugs.....	18
1.8.1	Orphenadrine Citrate.....	18
1.8.2	Theophylline Anhydrous.....	20
	Aim of the study	22

CHAPTER TWO

(EXPEREMENTS)

2.1	Materials.....	23
2.2	Instruments.....	23
2.3	Methods.....	24
2.3.1	Characterization of Orphenadrine Citrate and Theophylline Anhydrous.....	24

2.3.2	Preparation of Chitosan Polymer.....	25
2.3.3	Characterization of Chitosan Polymer.....	26
2.3.4	Preparation of Phosphate Buffer Solution.....	29
2.3.5	Formulation of Orphenadrine Citrate Chitosan Matrix Tablets.....	29
2.3.6	Formulation of Theophylline Chitosan Matrix Tablets	29
2.3.7	Physical Parameter Measurements of Orphenadrine Citrate and Theophylline Chitosan Matrix Tablets....	32
2.3.8	Effect of Drug on Physical Properties of the Prepare Chitosan Matrix Tablets.....	32
2.3.9	Effect of Chitosan Concentrations on the Physical Properties of the Prepared Chitosan Matrix Tablets.....	32
2.3.10	Effect of Compression Forces on the Physical Properties of the Prepared Chitosan Matrix Tablets....	33
2.3.11	Effect of Compression Forces on the Physical Properties of the Prepared Chitosan Matrix Tablets...	33
2.3.12	Comparison Between the Release of Orphenadrine Citrate from Chitosan matrix tablets and norflex®.....	33
2.3.13	Preparation of Chitosan Hydrochloride salt.....	33
2.3.14	Preparation of Chitosan Acetate salt.....	34
2.3.15	Characterization of Chitosan Hydrochloride and Chitosan Acetate.....	34
2.3.16	Formulation of Orphenadrine Citrate and Theophylline Anhydrous Chitosan Hydrochloride Matrix Tablets.....	34
2.3.17	Formulation of Orphenadrine Citrate and Theophylline Chitosan Acetate Matrix Tablets.....	34
2.3.18	Dissolution Rates Measurement of Orphenadrine Citrate and Theophylline anhydrous Chitosan HCl and Acetate Matrix Tablets	37
2.4	Statistical Analysis.....	37

CHAPTER THREE

(RESULTS AND DISSCUSION)

3.1	Characterization of Orphenadrine Ctrate.....	38
3.1.1	Determiation of Melting Point.....	38
3.1.2	Determiation of λ max.....	38
3.1.3	Calibration Curves.....	38
3.1.4	Determiation of Solubilities.....	38
3.2	Characterization of Theophylline Anhydrous.....	39
3.2.1	Determiation of Melting Point.....	39
3.2.2	Determiation of λ max.....	39
3.2.3	Calibration Curves.....	39

3.2.4	Determination of Solubilities.....	39
3.3	Preparation of Chitosan Polymer.....	43
3.3.1	Separation of Chitin Polymer.....	43
3.3.2	Preparation of Chitosan from Chitin.....	43
3.3.3	Purification of Chitosan Polymer.....	43
3.4	Characterization of Chitosan Polymer.....	44
3.5	Preparation of Chitosan Matrix Tablets.....	48
3.6	Effect of Drug on Physical Properties of Chitosan Matrix Tablets.....	50
3.7	Effect of Chitosan Concentrations on the Physical Properties of Prepared Chitosan Matrix Tablets.....	62
3.8	Effect of Compression Forces on the Physical Properties of Chitosan Matrix Tablets.....	67
3.9	Comparison Between the Release of Drug From Chitosan Matrix Tablets and Capsules.....	72
3.10	Comparison Between the Release of Orphenadrine Citrate from Chitosan Matrix Tablets and Norflex®	77
3.11	Preparation of Chitosan Hydrochloride and Acetate Salts.....	79
3.12	Characterization of Chitosan Hydrochloride & Chitosan Acetate.....	79
3.13	Dissolution Rates Measurement of Orphenadrine Citrate & Theophylline Anhydrous Chitosan Hydrochloride Matrix Tablets and Chitosan Acetate Matrix Tablets	81

CHAPTER FOUR

(CONCLUSION)

Conclusion	84
------------------	----

REFERENCES	86
-------------------------	----

LIST OF TABLES

Table No.	Description	Pages No.
1	Formulations of Orphenadrine Citrate Chitosan Matrix Tablets Using Different Concentrations of Chitosan.	30
2	Formulations of Theophylline Anhydrous Chitosan Matrix Tablets Using Different Concentrations of Chitosan.	31
3	Formulations of Orphenadrine Citrate and Theophylline Anhydrous Chitosan HCl Matrix Tablets Using Different Concentrations of Chitosan HCl.	35
4	Formulations of Orphenadrine Citrate and Theophylline Anhydrous Chitosan Acetate Matrix Tablets Using Different Concentrations of Chitosan Acetate.	36
5	Effect of Drug on the Hardness of Orphenadrine Citrate (Formula 2 and 4) and Theophylline Anhydrous (Formulas 7 and 9) Chitosan Matrix tablets at Compression Force of 38×10^3 psi and Different Chitosan Concentrations.	50
6	Effect of Chitosan Concentration on the Hardness of Orphenadrine Citrate and Theophylline Anhydrous Chitosan Matrix Tablets at 38×10^3 psi Compression Force.	63
7	Effect of Compression Force on the Hardness of Orphenadrine Citrate (Formulas 1, 3 and 5) and Theophylline Anhydrous (Formulas 6, 8 and 10) Chitosan Matrix Tablets.	68
8	Effect of Compression Force on the Dissolution Rates Constant of Orphenadrine Citrate (Formulas 1, 3 and 5) and Theophylline Anhydrous (Formulas 6, 8 and 10) Chitosan Matrix Tablets at pH 1.2, 6.8 Dissolution Media and 37°C	71
9	Time Required for 50% Release of Orphenadrine Citrate (Formula 4) and Theophylline Anhydrous (Formula 9) Chitosan Matrix Tablets at A Compression Force of $38 \cdot 10^3$ psi, pH (1.2 and 6.8) Dissolution Media and 37°C	74

LIST OF FIGURES

Figure No.	Description	Page No.
1	U type capillary viscometer	28
2	Calibration curve of orphenadrine citrate in 0.1N HCl	40
3	Calibration curve of orphenadrine citrate in phosphate buffer pH 6.8.	40
4	Calibration curve of orphenadrine citrate in phosphate buffer pH 6.8 adjusted to 1.2.	41
5	Calibration curve of theophylline anhydrous in 0.1N HCl.	41
6	Calibration curve of theophylline anhydrous in phosphate buffer pH 6.8.	42
7	Calibration curve of theophylline anhydrous in phosphate buffer pH 6.8 adjusted to 1.2.	42
8	Represented the prawn as (a)-back review, (b)- side review and (c)-dry prawn shells.	45
9	Represented chitosan as (a)- hydrogel and (b)-powder.	46
10	I.R spectrum of 100% deacetylated chitosan.	47
11	I.R spectrum of 70% deacetylated chitosan	47
12	Plots of reduced and inherent viscosity versus concentration for chitosan in 0.1M acetic acid with 0.2M NaCl solvent for determination of intrinsic viscosity.	49
13	Effect of type of drug on release rate of orphenadrine citrate (formulas 2 and 4) and theophylline anhydrous (formulas 7 and 9) chitosan matrix tablets at a compression force of 38×10^3 psi compression force and 37°C .	53
14	First order plots of drug release data for orphenadrine citrate (formulas 2 and 4) and theophylline anhydrous (formulas 7 and 9) chitosan matrix tablets at 38×10^3 psi compression force and 37°C .	56
15	Square root of time plots of drug release data for orphenadrine citrate (formulas 2 and 4) and theophylline anhydrous (formulas 7 and 9) chitosan matrix tablets at 38×10^3 psi compression force and 37°C .	56

Figure No.	Description	Page No.
16	Drug release rate versus reciprocal of amount released for orphenadrine citrate (formulas 2 and 4) and theophylline anhydrous (formulas 7 and 9) chitosan matrix tablets at 38×10^3 psi compression force and 37°C	57
17	Drug release rate versus amount released for orphenadrine citrate (formulas 2 and 4) and theophylline anhydrous (formula 7 and 9) chitosan matrix tablets at 38×10^3 psi compression force and 37°C .	58
18	Log fraction released versus log time for orphenadrine citrate (formula 4) and theophylline anhydrous (formula 9) chitosan matrix tablets at pH 1.2 and 6.8 dissolution media, 38×10^3 psi compression force and 37°C .	61
19	Log fraction released versus log time for orphenadrine citrate (formula 4) and theophylline anhydrous (formula 9) chitosan matrix tablets at pH 1.2 and 6.8 dissolution media, 38×10^3 psi compression force and 37°C .	61
20	Effect of chitosan concentration on release of orphenadrine citrate from chitosan matrix tables at $38 \cdot 10^3$ psi compression force and 37°C .	65
21	Effect of chitosan concentration on release of theophylline anhydrous from chitosan matrix tables at $38 \cdot 10^3$ psi compression force and 37°C .	65
22	Import of water and drug diffusivity, erosion velocity and polymer relaxation velocity on the mechanisms that controlled drug release.	66
23	Effect of compression forces on hardness of orphenadrine citrate (formulas 1, 3 and 5) and theophylline anhydrous (formulas 6, 8 and 10) chitosan matrix tablets .	69
24	Dissolution profiles for orphenadrine citrate and theophylline anhydrous from 40% chitosan matrix tablets and capsules at 37°C .	75
25	Erosion of chitosan matrix tablet in 0.1N HCl .	76
26	Comparison of dissolution profile of orphenadrine citrate chitosan matrix tablets(formula 3) at $37 \cdot 10^3$ psi compression force and 37°C with norflex [®] tablets.	78

Figure No.	Description	Page No.
27	IR spectrum of chitosan HCl.	80
28	IR spectrum of chitosan acetate.	80
29	Release of orphenadrine citrate and theophylline anhydrous from chitosan HCl matrix tablets at $38 \cdot 10^3$ psi compression force, 0.1N HCl and 37°C .	82
30	Release of orphenadrine citrate and theophylline anhydrous from chitosan acetate matrix tablets at $38 \cdot 10^3$ psi compression force, 0.1N HCl and 37°C .	83

SCHEME

Scheme No.	Description	Page No.
1	The chemical reaction involved in the conversion of chitin to chitosan.	15